Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Toppari, Jorma / Turan, Serap Demircioglu


IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

Online
ISSN
2191-0251
See all formats and pricing
More options …
Volume 32, Issue 10

Issues

The effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria: findings from a large national cohort

Tobin Joseph
  • Department of Paediatric and Adolescent Endocrinology, University College London Hospital, London, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Joanna Ting
  • Department of Paediatric and Adolescent Endocrinology, University College London Hospital, London, UK
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gary Butler
  • Corresponding author
  • Department of Paediatric and Adolescent Endocrinology, University College London Hospital, London, UK
  • UCL Great Ormond Street Institute of Child Health, London, UK
  • Gender Identity Development Service, Tavistock and Portman NHS Trust, London, UK
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-08-31 | DOI: https://doi.org/10.1515/jpem-2019-0046

Abstract

Background

More young people with gender dysphoria (GD) are undergoing hormonal intervention starting with gonadotropin-releasing hormone analogue (GnRHa) treatment. The impact on bone density is not known, with guidelines mentioning that bone mineral density (BMD) should be monitored without suggesting when. This study aimed to examine a cohort of adolescents from a single centre to investigate whether there were any clinically significant changes in BMD and bone mineral apparent density (BMAD) whilst on GnRHa therapy.

Methods

A retrospective review of 70 subjects aged 12–14 years, referred to a national centre for the management of GD (2011–2016) who had yearly dual energy X-ray absorptiometry (DXA) scans. BMAD scores were calculated from available data. Two analyses were performed, a complete longitudinal analysis (n=31) where patients had scans over a 2-year treatment period, and a larger cohort over the first treatment year (n=70) to extend the observation of rapid changes in lumbar spine BMD when puberty is blocked.

Results

At baseline transboys had lower BMD measures than transgirls. Although there was a significant fall in hip and lumbar spine BMD and lumbar spine BMAD Z-scores, there was no significant change in the absolute values of hip or spine BMD or lumbar spine BMAD after 1 year on GnRHa and a lower fall in BMD/BMAD Z-scores in the longitudinal group in the second year.

Conclusions

We suggest that reference ranges may need to be re-defined for this select patient cohort. Long-term BMD recovery studies on sex hormone treatment are needed.

Keywords: BMI; bone mineral density; gender dysphoria; GnRHa treatment; sex steroids

References

  • 1.

    Susman EJ, Houts RM, Steinberg L, Belsky J, Cauffman E, et al. Longitudinal development of secondary sexual characteristics in girls and boys between ages 91/2 and 151/2 years. Arch Pediatr Adolesc Med 2010;164:166–73.CrossrefPubMedGoogle Scholar

  • 2.

    Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555–63.CrossrefPubMedGoogle Scholar

  • 3.

    Butler G, De Graaf N, Wren B, Carmichael P. Assessment and support of children and adolescents with gender dysphoria. Arch Dis Child 2018;103:631–6.PubMedWeb of ScienceGoogle Scholar

  • 4.

    Klink D, Caris M, Heijboer A, Van Trotsenburg M, Rotteveel J. Bone mass in young adulthood following gonadotropin-releasing hormone analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metab 2015;100:E270–5.Web of ScienceCrossrefPubMedGoogle Scholar

  • 5.

    Vlot MC, Klink DT, den Heijer M, Blankenstein MA, Rotteveel J, et al. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 2017;95:11–9.CrossrefWeb of ScienceGoogle Scholar

  • 6.

    Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017;102:3869–903.PubMedCrossrefGoogle Scholar

  • 7.

    Levine MA. Assessing bone health in children and adolescents. Indian J Endocrinol Metab 2012;16(Suppl 2):S205–12.PubMedGoogle Scholar

  • 8.

    Crabtree NJ, Shaw NJ, Bishop NJ, Adams JE, Mughal MZ, Arundel P, et al. Amalgamated reference data for size-adjusted bone densitometry measurements in 3598 children and young adults – the ALPHABET study. J Bone Miner Res 2017;32:172–80.Web of ScienceCrossrefGoogle Scholar

  • 9.

    Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van de Peer F, et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 2012;97:2503–11.Web of ScienceCrossrefPubMedGoogle Scholar

  • 10.

    Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab 1997;82:57–62.PubMedGoogle Scholar

  • 11.

    Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Osteoporosis in children and adolescents etiology and management. Pediatr Drugs 2005;7:295–323.CrossrefGoogle Scholar

  • 12.

    Cohen-Kettenis PT, Klink D. Adolescents with gender dysphoria. Best Pract Res Clin Endocrinol Metab 2015;29:485–95.PubMedCrossrefGoogle Scholar

About the article

Corresponding author: Professor Gary Butler, Department of Paediatric and Adolescent Endocrinology, University College London Hospital, 250 Euston Road, London NW1 2PQ, UK; UCL Great Ormond Street Institute of Child Health, London, UK; and Gender Identity Development Service, Tavistock and Portman NHS Trust, London, UK, Phone: +44 (0)20 344 79455


Received: 2019-01-22

Accepted: 2019-07-17

Published Online: 2019-08-31

Published in Print: 2019-10-25


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. The project was conceived by GB. Data collection and analysis was conducted by TJ and JT with input from GB as part of a UCL Medical School academic programme.

Research funding: None. All scans were conducted as part of the NHS routine care programme.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Journal of Pediatric Endocrinology and Metabolism, Volume 32, Issue 10, Pages 1077–1081, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2019-0046.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Comments (0)

Please log in or register to comment.
Log in